Newsroom

LATEST PUBLICATIONS

Hydroa Vacciniforme-like Lymphoma: A Chronic EBV+ Lymphoproliferative Disorder with Risk to Develop a Systemic Lymphoma

Invivoscribe Marketing2021-02-18T21:10:55-08:00October 31st, 2013|

Paediatric and Adolescent Elevated Conjunctival Lesions in the Plical Area: Lymphoma or Reactive Lymphoid Hyperplasia?

Invivoscribe Marketing2021-02-18T21:14:44-08:00October 25th, 2013|

Diagnostic Utility of a Clonality Test for Lymphoproliferative Diseases in Koreans Using the BIOMED-2 PCR Assay

Invivoscribe Marketing2021-02-18T21:18:36-08:00October 25th, 2013|

Dried Blood Spot Sampling for Detection of Monoclonal Immunoglobulin Gene Rearrangement

Invivoscribe Marketing2021-02-18T21:22:32-08:00August 13th, 2013|

EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations

Invivoscribe Marketing2021-02-18T21:25:10-08:00October 26th, 2012|

CONFERENCES

No conferences from the last year found.

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

CE-IVD

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

CE-IVD

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Myeloma

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

Newsroom

Newsroom

LATEST PUBLICATIONS

Hydroa Vacciniforme-like Lymphoma: A Chronic EBV+ Lymphoproliferative Disorder with Risk to Develop a Systemic Lymphoma

Paediatric and Adolescent Elevated Conjunctival Lesions in the Plical Area: Lymphoma or Reactive Lymphoid Hyperplasia?

Diagnostic Utility of a Clonality Test for Lymphoproliferative Diseases in Koreans Using the BIOMED-2 PCR Assay

Dried Blood Spot Sampling for Detection of Monoclonal Immunoglobulin Gene Rearrangement

EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations

LATEST PRESS

CONFERENCES

Global Search

SEARCH BY KEYWORD

Global Search

SEARCH BY KEYWORD

Looking for Product Documents?
Try our New Document Search Feature ⟶

Looking for Product Documents?
Try our New Document Search Feature ⟶

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

CE-IVD

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

CE-IVD

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Myeloma

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

Newsroom

Newsroom

LATEST PUBLICATIONS

Hydroa Vacciniforme-like Lymphoma: A Chronic EBV+ Lymphoproliferative Disorder with Risk to Develop a Systemic Lymphoma

Paediatric and Adolescent Elevated Conjunctival Lesions in the Plical Area: Lymphoma or Reactive Lymphoid Hyperplasia?

Diagnostic Utility of a Clonality Test for Lymphoproliferative Diseases in Koreans Using the BIOMED-2 PCR Assay

Dried Blood Spot Sampling for Detection of Monoclonal Immunoglobulin Gene Rearrangement

EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations

LATEST PRESS

CONFERENCES

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.